GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3)
In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.
Video GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3) -Copyright ©2023 by PanNash™ Initiative - All rights reserved.
Would you like to read more?
Prof. Sven Francque
Delving into the Latest Advancements in MASLD Treatment: Key Insights from Prof. Wong’s presentations at AASLD
Explore Prof. Wong's insights on MASLD treatment advancements from AASLD, featuring key drugs like Resmetirom, Lanifibranor, and Semaglutide with a…
International NASH Day 2023: Empowering Healthcare Professionals
On International NASH Day 2023, PanNASH amplifies the importance of NASH awareness, education, and action. Learn about the complex multisystem…
Nordic NASH Symposium
PanNASH speaker; Dr. Stephen Harrison takes part in the Nordic NASH symposium which aims to discuss management and diagnosis strategies…
The role of circadian clocks in the pathogenesis of NAFLD
The circadian clock controls rhythms responsible for regulating bodily functions, e.g., appropriate eating times. When this clock becomes disrupted due…
Hepatocellular carcinoma surveillance in NAFLD patients
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver…
MAFLD and inflammatory bowel disease: a prospective cohort study
MAFLD and inflammatory bowel disease: a prospective cohort study
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
B cells aggravate NASH: an innate and adaptive signalling
In this study, F. Barrow et al. (University of Minnesota Medical School, Minneapolis, USA) report that NASH livers accumulate B…
NAFLD: from drivers to targets
In this review, A. Santos-Laso et al. (Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute, Santander, Spain) summarise the…
NASH: an Overview Through 200 Years of Clinical Research
Although the term 'fatty liver hepatitis' first appeared in 1962, it was in 1980 that the term 'non-alcoholic steatohepatitis' (NASH)…
Immune cell-mediated features of NASH
In this review, T. Huby and E. L. Gautier (Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France) discuss “current concepts…
Steatohepatitis: hypothesis for a pathomechanism
In this article, P. M. Abuja et al. (Medical University of Graz, Austria) propose that steatohepatitis develops in four phases…
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
